|

Dalpiciclib 150mg Clinical Trials

2 actively recruiting trials

No change since May 2026

Pipeline

Phase 1: 1Phase 2: 1

Top Sponsors

  • wanghaibo1
  • West China Hospital1

Indications

  • Cancer2
  • HR-positive, HER2-negative Advanced Breast Cancer1
  • Head and Neck Squamous Cell Carcinoma1
  • Breast Cancer1

Other2 trials

Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer
Phase 2
Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.